# Metformin in Chronic Kidney Disease

## Executive Summary

**💡 Key Points**

- The FDA **replaced** the original serum creatinine-based black box contraindication with an **eGFR-based framework** in April 2016: contraindicated at eGFR \<30, cautious continuation at eGFR 30–44, normal use ≥45.
- The absolute risk of metformin-associated lactic acidosis (MALA) at therapeutic doses is extremely low — approximately **3–10 cases per 100,000 patient-years**.
- Target trial emulation (TTE) is a causal inference framework that applies a pre-specified hypothetical RCT protocol to observational data, systematically preventing immortal time bias, prevalent user bias, and confounding by indication.
- A 2024 Scottish TTE study (N=4,278) found that **stopping metformin was associated with 26% higher 3-year all-cause mortality** (HR 1.26; 95% CI 1.10–1.44) with no difference in MACE, an association requiring confirmation and not a change to the eGFR \<30 contraindication.
- Metformin’s primary mechanism is **mild, self-limiting inhibition of mitochondrial complex I** — the same pathway that at toxic concentrations underlies MALA.

## 1. The FDA Black Box Warning: Then and Now

### 1.1 The Original Creatinine-Based Contraindication

When metformin was approved by the FDA in 1994, its labeling carried a boxed warning prohibiting use in patients with elevated serum creatinine — specifically, SCr ≥1.4 mg/dL in women and ≥1.5 mg/dL in men. This threshold was adopted partly by analogy with **phenformin**, a related biguanide withdrawn in 1977 due to an unacceptably high rate of lactic acidosis driven by phenformin’s far greater affinity for mitochondrial complex I and much longer half-life.

### 1.2 The 2016 FDA Revision: eGFR-Based Framework

| eGFR (mL/min/1.73 m²) | FDA Guidance |
|----|----|
| ≥60 | Use normally; monitor eGFR annually |
| 45–59 | Continue with caution; monitor eGFR every 3–6 months |
| 30–44 | Do not **initiate**; reassess if already on metformin; consider dose reduction; monitor q3 months |
| \<30 | **Contraindicated** (absolute) — but see Scottish TTE data below |

FDA 2016 eGFR-Based Metformin Guidance

**💡 Clinical Pearl**

The 2016 revision **did not eliminate** the black box warning — it redefined the threshold using eGFR rather than creatinine and moderated it from an absolute contraindication in CKD 3a/3b to a nuanced eGFR-stratified approach. Contrast guidance was also updated: hold metformin at the time of IV contrast procedures **only** in patients with eGFR 30–60, liver disease, alcoholism, or heart failure.

### 1.3 ADA/KDIGO 2022 Alignment

The ADA–KDIGO 2022 Consensus Report and ADA Standards of Care 2026 both endorse the eGFR-stratified framework while positioning **SGLT2 inhibitors** as preferred agents for cardiorenal protection independent of A1C, with metformin retained as backbone glycemic therapy where tolerated.

## 2. Metformin-Associated Lactic Acidosis (MALA)

### 2.1 Definition and Incidence

MALA is defined by blood lactate \>5 mmol/L, pH \<7.35, and plasma metformin \>5 mg/L. The true incidence at therapeutic doses is very low: **3–10 cases per 100,000 patient-years**. Cochrane systematic reviews have not demonstrated excess lactic acidosis risk compared to other antidiabetic agents when patients are appropriately selected.

### 2.2 Why the Kidney Matters

Metformin is **not metabolized by the liver** — it is eliminated almost entirely unchanged by the kidney via active tubular secretion through organic cation transporters (OCT2), with ~90% cleared renally within 24 hours. As eGFR falls, plasma concentrations rise, and with accumulation comes mitochondrial complex I inhibition sufficient to shift metabolism from oxidative phosphorylation to anaerobic glycolysis.

### 2.3 Risk Factors for MALA Beyond Renal Impairment

| Risk Factor | Mechanism |
|----|----|
| Acute kidney injury | Sudden reduction in metformin clearance |
| Hepatic failure | Impairs lactate clearance via Cori cycle |
| Acute decompensated heart failure | Tissue hypoperfusion → type A lactic acidosis |
| Excessive alcohol use | Potentiates effect on lactate metabolism |
| Respiratory failure | Impaired oxygen delivery |
| Drugs reducing OCT2 secretion | Vandetanib, dolutegravir, cimetidine, ranolazine |
| IV contrast (at-risk patients) | Transient AKI risk, especially intra-arterial |

**💡 Clinical Pearl**

MALA is predominantly a disease of **accumulation states**, not of normal renal function. The phenformin analogy is a pharmacologic red herring — metformin’s affinity for complex I is orders of magnitude lower. Distinguish MALA from **MAH** (metformin-associated hyperlactatemia) — elevated lactate without acidosis, which is far more common and often asymptomatic.

## 3. Mechanism of Action: The Mitochondrial Axis

### 3.1 Entry into Mitochondria

Metformin is a positively charged hydrophilic molecule that enters cells via **OCT1 (liver)** and **OCT2 (kidney)** and accumulates in the mitochondrial matrix driven by the large negative mitochondrial membrane potential (~−180 mV). This electrophoretic accumulation explains the concentration-dependence of its effects.

### 3.2 Complex I Inhibition: The Primary Mechanism

Metformin inhibits **Complex I (NADH:ubiquinone oxidoreductase)** of the mitochondrial electron transport chain. The downstream consequences:

1.  **Reduced electron flow** through ETC → decreased NADH oxidation → elevated NADH/NAD+ ratio
2.  **Decreased ATP synthesis** via OXPHOS → rising AMP:ATP ratio
3.  **AMPK activation** via AMP-mediated allosteric activation and phosphorylation at Thr172 by LKB1
4.  **Suppression of hepatic gluconeogenesis** via AMPK-dependent TORC2 phosphorylation and AMPK-independent fructose-1,6-bisphosphatase inhibition by accumulated AMP

**⚠ Critical Concept**

Metformin has several proposed concentration-dependent mechanisms. Mitochondrial effects contribute to toxicity during accumulation, but its clinical benefit and lactic-acidosis risk should not be reduced to a single established pathway.

### 3.3 AMPK-Independent Mechanisms

- **mGPDH inhibition:** Raises cytosolic NADH/NAD+ ratio, reduces lactate-to-pyruvate conversion for gluconeogenesis. Does NOT require AMPK activation.
- **Lysosomal PEN2–v-ATPase–Ragulator pathway:** Metformin binds PEN2 on the lysosomal membrane, enabling local AMPK phosphorylation independent of AMP:ATP ratio changes — relevant at low, clinically therapeutic concentrations.
- **Gut-mediated effects:** Incretin modulation, altered bile acid metabolism, enrichment of *Akkermansia muciniphila*.

### 3.4 How Complex I Inhibition Causes MALA

At supratherapeutic concentrations:

1.  Severe Complex I blockade → massive shift from OXPHOS to anaerobic glycolysis → massive lactate generation
2.  Pyruvate carboxylase inhibition → pyruvate diverted to lactate
3.  Impaired AMP buffering → hydrogen ion accumulation → metabolic acidosis
4.  Reduced hepatic lactate uptake → failure of the Cori cycle
5.  Progressive acidosis → myocardial depression, catecholamine resistance, shock, multiorgan failure

## 4. Target Trial Emulation: Framework and Methodology

### 4.1 The Problem with Conventional Observational Studies

| Bias | Description | Direction |
|----|----|----|
| Confounding by indication | Sicker patients less likely to receive treatment | Can bias the apparent benefit or harm depending on treatment selection |
| Immortal time bias | Follow-up before treatment misattributed to treatment group | Makes drug appear protective (spuriously) |
| Prevalent user bias | Including long-term survivors selects healthy adherers | Distorts comparisons |
| Healthy user bias | Adherers also adhere to lifestyle factors | Makes treatment look better |
| Depletion of susceptibles | Early adverse events eliminate sensitive individuals | Attenuates apparent harm |

### 4.2 The TTE Framework (Hernán and Robins, 2016)

**Step 1:** Specify the protocol of a hypothetical RCT (the “target trial”).

**Step 2:** Emulate that target trial in observational data as closely as possible.

**Clone-Censor-Weight (CCW) Design:** Each eligible individual is “cloned” at baseline and assigned to both strategies simultaneously. A clone is censored when it deviates from its assigned strategy. Inverse probability of censoring weighting (IPCW) reweights remaining observations.

## 5. The Scottish Target Trial Emulation Study (AJKD, 2025; online 2024)

### 5.1 Study Overview

Lambourg et al. published a nationwide Scottish TTE study in *American Journal of Kidney Diseases* (November 2024, PMID: 39521399) addressing: in patients with T2DM already on metformin who develop **CKD stage 4 (eGFR \<30)**, does stopping vs. continuing metformin affect mortality?

### 5.2 Study Population

Derived from the Scottish Diabetes Research Network — National Diabetes Study (SDRN-NDS), covering \>99% of people with diabetes in Scotland. **Final cohort: 4,278 patients.** Within 6 months of reaching CKD stage 4, 1,713 (40.1%) discontinued metformin.

### 5.3 TTE Design Elements

| Target Trial Element | Implementation |
|----|----|
| Eligibility | Incident CKD stage 4, pre-existing metformin use, no RRT |
| Treatment strategies | “Stop within 6 months” vs. “Continue for ≥6 months” |
| Assignment | Clone-censor-weight at index date |
| Grace period | 6 months post-CKD stage 4 diagnosis |
| Primary outcome | All-cause mortality |
| Secondary outcome | MACE (composite fatal/non-fatal CV events) |
| Exposure data | Pharmacy dispensation records (superior to prescription data) |

### 5.4 Key Results

**⚠ Practice-Challenging Results**

**Primary Outcome — All-Cause Mortality:**

- 3-year survival: **70.5%** (continue) vs. **63.7%** (stop)
- HR for stopping vs. continuing: **1.26** (95% CI 1.10–1.44) — CCW analysis
- Marginal structural models confirmed: HR **1.34** (95% CI 1.08–1.67)

**Secondary Outcome — MACE:** HR 1.05 (95% CI 0.88–1.26) — no significant difference

Stopping metformin was associated with a clinically and statistically significant **~7% absolute reduction in 3-year survival**, without a corresponding reduction in MACE. This observational mortality comparison does not establish the safety of continuing metformin below the labeled kidney-function threshold.

### 5.5 Strengths and Limitations

**Strengths:** Nationwide cohort (\>99% diabetes capture), A carefully specified TTE can reduce time-related and selection biases, pharmacy dispensation data for accurate exposure, 3-year follow-up, concordant primary and sensitivity analyses.

**Limitations:** Residual unmeasured confounding (frailty, physician practice style), limited SGLT2i/GLP-1 RA use during study period (2010–2019), CKD stage 4 misclassification risk, cause of death not fully adjudicated, external validity limited to Scotland-like populations.

**💡 Clinical Pearl**

This study raises a research question but cannot establish a causal survival benefit or override current prescribing restrictions. Current labeling contraindicates metformin below eGFR 30 mL/min/1.73 m²; randomized evidence would be needed to change that standard.

## 6. Nephrology-Specific Practice Considerations

### 6.1 Current Monitoring Framework (follow the applicable product label and clinical guideline)

| eGFR | Action |
|----|----|
| ≥60 | Continue, annual monitoring |
| 45–59 | Continue, monitor q3–6 months |
| 30–44 | Do not initiate; if already on, reassess, consider 50% dose reduction, monitor q3 months |
| \<30 | Contraindicated under current labeling; discontinue and choose an appropriate alternative |
| Any eGFR | Hold with acute illness, AKI, IV contrast (if eGFR 30–60), major surgery |

[Current metformin prescribing information (DailyMed)](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b8004451-7b26-425b-b5ea-cbb1b08e30e3).

### 6.2 Sick Day Rules — Critical for CKD Patients

**⚠ Sick Day Instructions**

Patients receiving metformin within its labeled kidney-function range should have explicit instructions: **hold metformin** when volume-depleted, febrile, with GI illness, or beginning any nephrotoxic drug or contrast procedure. This may reduce risk but does not eliminate it; provide a clear plan for reassessment and restarting when appropriate.

### 6.3 Positioning in the Era of SGLT2i and GLP-1 RA

The ADA/KDIGO 2022 consensus therapeutic hierarchy:

1.  **SGLT2 inhibitors** (empagliflozin, dapagliflozin, canagliflozin) — for eGFR ≥20–25, cardiorenal protection independent of A1C
2.  **GLP-1 receptor agonists** (semaglutide, dulaglutide) — for ASCVD risk reduction and weight management
3.  **Metformin** — as backbone oral agent for glycemic control, adjunct to cardioprotective agents

The Scottish data suggests metformin should retain a meaningful role even as SGLT2i become standard — within its appropriate kidney-function range. The observational data do not justify routine use in CKD stage 4.

## 7. Summary and Key Points

1.  The original creatinine-based black box warning has been replaced by an **eGFR-based framework** (FDA 2016).
2.  **MALA is real but rare** (3–10 cases/100,000 patient-years) and is primarily a disease of metformin accumulation.
3.  Metformin has multiple proposed cellular mechanisms; accumulation during severe kidney impairment or acute illness increases toxicity risk.
4.  **Target trial emulation** is a framework to reduce design-related biases; it does not eliminate residual confounding.
5.  The **2024 Scottish TTE study** (AJKD, PMID 39521399) found stopping metformin associated with 26% higher 3-year mortality with no MACE difference, an association requiring confirmation and not a change to the eGFR \<30 contraindication.
6.  Current labeling contraindicates metformin when **eGFR is below 30**; select another glucose-lowering strategy and reassess during acute illness.

## References

1.  Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. *Diabetes Care.* 2011;34(6):1431–1437. [PubMed](https://pubmed.ncbi.nlm.nih.gov/21617112/)
2.  FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. April 2016. [FDA](https://www.fda.gov/files/drugs/published/Drug-Safety-Communication-FDA-revises-warnings-regarding-use-of-the-diabetes-medicine-metformin-in-certain-patients-with-reduced-kidney-function-%28PDF%29.pdf)
3.  Inzucchi SE, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. *JAMA.* 2014;312(24):2668–2675. [PubMed](https://pubmed.ncbi.nlm.nih.gov/25536258/)
4.  Dyatlova N, Tobarran NV, Kannan L, et al. Metformin-Associated Lactic Acidosis (MALA). *StatPearls*. 2023. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35593810/)
5.  Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. *Am J Epidemiol.* 2016;183(8):758–764. [PubMed](https://pubmed.ncbi.nlm.nih.gov/26994063/)
6.  Lambourg EJ, Fu EL, McGurnaghan S, et al. Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study. *Am J Kidney Dis*. 2025;85(2):196-204.e1. [DOI](https://doi.org/10.1053/j.ajkd.2024.08.012) \| [PubMed](https://pubmed.ncbi.nlm.nih.gov/39521399/)
7.  Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. *Diabetologia*. 2017;60(9):1577-1585. [DOI](https://doi.org/10.1007/s00125-017-4342-z) \| [PubMed](https://pubmed.ncbi.nlm.nih.gov/28776086/)
8.  Feng J, Wang X, Ye X, et al. Mitochondria as an important target of metformin: The mechanism of action, toxic and side effects, and new therapeutic applications. *Pharmacol Res*. 2022;177:106114. [DOI](https://doi.org/10.1016/j.phrs.2022.106114) \| [PubMed](https://pubmed.ncbi.nlm.nih.gov/35124206/)
9.  Salpeter SR, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. *Cochrane Database Syst Rev.* 2010;(4):CD002967. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20393934/)
10. ADA Standards of Care in Diabetes—2026. Section 11: Chronic Kidney Disease and Risk Management. *Diabetes Care.* 2026;49(Suppl 1):S246–S268. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41358881/)
11. Fu EL, et al. Target trial emulation to improve causal inference from observational data. *J Am Soc Nephrol.* 2023;34(8):1291–1304. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37131279/)

### Also on this topic

The same subject at other levels of depth.

- **Primer chapter:** [Chapter 11: Chronic Kidney Disease (CKD)](https://urinenephrology.org/nephrology-textbook/chapters/chapter-09-ckd.html)
- **Patient handout:** [What Is Chronic Kidney Disease?](https://urinenephrology.org/patient-handouts/what-is-ckd.html)


---

[Website version](https://urinenephrology.org/mastery/ckd-advanced/metformin-ckd.html) · Markdown synchronized October 3, 2026.